O estudo que presentamos hoxe trata sobre que fármaco empregar cando non controlamos a HTA con tres fármacos: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, doubleblind, crossover trial. Bryan Williams, Thomas M. MacDonald, Steve Morant, David J. Webb, Peter Sever, Gordon McInnes, Ian Ford, J. Kennedy Cruickshank, Mark J. Caulfi eld, Jackie Salsbury, Isla Mackenzie, Sandosh Padmanabhan, Morris J. Brown, for The British Hypertension Society’s PATHWAY Studies Group*. Lancet. 2015 Nov 21; 386(10008): 2059-2068
